12 research outputs found
Supplementary Figure S6 from Neoantigen Targetability in Progressive Advanced Melanoma
Expression of tumor associated antigens in early and later metastatic lesions.</p
Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
Eluted tumor-associated antigen-derived peptides.</p
Supplementary Figure S3 from Neoantigen Targetability in Progressive Advanced Melanoma
T cell recognition of melanoma cell lines derived from early and later metastatic lesions.</p
Supplementary Figure S5 from Neoantigen Targetability in Progressive Advanced Melanoma
Putative neoantigens in early and later metastatic lesions.</p
Supplementary Figure S2 from Neoantigen Targetability in Progressive Advanced Melanoma
HLA class I and II expression on melanoma cell lines derived from early and later metastatic lesions.</p
Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
Whole-exome sequencing strategy.</p
Supplementary Figure S1 from Neoantigen Targetability in Progressive Advanced Melanoma
Immunohistochemical staining of proteins involved in T cell recognition and/or inhibition.</p
Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
Tumor characteristics.</p
Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
HLA class I genotypes as determined by exome and transcriptome sequencing.</p
Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
Tumor-associated antigen peptide sequences assessed for elution.</p